Comparative Pharmacology
Head-to-head clinical analysis: NUROMAX versus PAVULON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUROMAX versus PAVULON.
NUROMAX vs PAVULON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neuromuscular blocking agent; competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing depolarization and muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking transmission of nerve impulses to skeletal muscle.
0.1 mg/kg IV bolus, then 0.015 mg/kg IV as needed for neuromuscular blockade.
0.04-0.1 mg/kg IV bolus for intubation; maintenance: 0.01-0.015 mg/kg IV every 25-60 minutes as needed or continuous IV infusion: 1-2 mcg/kg/min.
None Documented
None Documented
Terminal half-life: 1.5-2.5 hours; prolonged in renal impairment (up to 5 hours) and hepatic disease
Terminal elimination half-life 100-120 minutes in adults with normal renal function; prolonged in renal impairment.
Renal: 80-90% unchanged; biliary: 10-20%
Renal 80-100% as unchanged drug and metabolites; biliary/fecal negligible (<5%).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent